Ubs Asset Management Americas Inc Point Biopharma Global Inc. Transaction History

Ubs Asset Management Americas Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$6.67 - $9.71 $205,109 - $298,592	30,751 Added 165.88%	49,289 $328,000
Q1 2023 May 15, 2023	SELL	$6.78 - $8.1 $123,396 - $147,420	-18,200 Reduced 49.54%	18,538 $134,000
Q3 2022 Nov 14, 2022	BUY	$7.24 - $10.31 $24,891 - $35,445	3,438 Added 10.32%	36,738 $283,000
Q2 2022 Aug 12, 2022	BUY	$5.6 - $9.5 $84,560 - $143,450	15,100 Added 82.97%	33,300 $226,000
Q4 2021 Feb 14, 2022	BUY	$4.83 - $9.75 $87,906 - $177,450	18,200 New	18,200 $101,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.